BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

ALKERMES PHARMACEUTICALS CORPORATION — Receipts Report

LD-2 disclosure · 1st Quarter - Report (No Activity)

ALKERMES PHARMACEUTICALS CORPORATION

via ARTEMIS STRATEGIES

1st Quarter (Jan 1 - Mar 31) · 2017Posted Jun 16, 2017Filing document ↗LDA record ↗

Coverage · No income or expenses were reported on this filing.

Client

Name: ALKERMES PHARMACEUTICALS CORPORATION
Description: Pharmaceuticals development and manufacturing
Location: Massachusetts · United States of America

Registrant

Firm: ARTEMIS STRATEGIES
Description: consultant
Location: Waterford, Virginia, United States of America

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.